evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

46 questions · 46 findings · 3 reviews · Kidney and Transplant

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 17 · 37%GRADE not reported 0 · 0%Very low 15 · 32.6%Low 11 · 23.9%Moderate 3 · 6.5%High 0 · 0%

Cyclosporin vs mycophenolate mofetil with pulse dexamethasone

Partial remission ( · idiopathic steroid‐resistant nephrotic syndrome in children

Cyclosporin showed no clear difference in treatment response at 52 weeks: partial remission (primary outcome 3) compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).

1 finding from 1 review

Cyclosporin vs mycophenolate mofetil with pulse dexamethasone

Sustainable remission between 52 and 78 weeks: complete or partial remission (primary outcome 1, 2, 3) · idiopathic steroid‐resistant nephrotic syndrome in children

Cyclosporin showed no clear difference in sustainable remission between 52 and 78 weeks: complete or partial… compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).

1 finding from 1 review

Cyclosporin vs mycophenolate mofetil with pulse dexamethasone

CKD or death: 50% decline in GFR by 78 weeks · idiopathic steroid‐resistant nephrotic syndrome in children

Cyclosporin showed no clear difference in CKD or death: 50% decline in GFR by 78 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).

1 finding from 1 review

Cyclosporin vs mycophenolate mofetil with pulse dexamethasone

Adverse effects (weeks 0 to 26): serious infection requiring hospitalisation · idiopathic steroid‐resistant nephrotic syndrome in children

Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): serious infection requiring… compared with mycophenolate mofetil with pulse dexamethasone (low certainty).

1 finding from 1 review

Cyclosporin vs mycophenolate mofetil with pulse dexamethasone

Adverse events: hypertension · idiopathic steroid‐resistant nephrotic syndrome in children

Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): hypertension compared with mycophenolate mofetil with pulse dexamethasone (low certainty).

1 finding from 1 review